An engineered Pichia pastoris fermentation platform that uses sequential reactors expressing PLA hydrolase and PHB depolymerase to simultaneously recycle and separate mixed bioplastics into valuable monomers. Leverages low-cost, scalable yeast hosts for extracellular enzyme production to enable sustainable, targeted enzymatic hydrolysis of bioplastic blends.
Mixed bioplastic waste streams containing polylactic acid (PLA) and polyhydroxyalkanoates (PHA) are difficult to recycle using conventional methods because the polymers degrade under overlapping conditions. This project addresses that challenge with a sequential yeast fermentation platform that selectively breaks down each polymer in a mixture, producing recoverable monomers such as lactic acid and PHB hydroxyalkanoate monomers.
The approach uses Pichia pastoris, a yeast known for high-yield extracellular enzyme production, low cost, and industrial scalability. By housing engineered P. pastoris strains expressing PLA hydrolase in a first reactor and PHB depolymerase in a second, the system enables step-wise, substrate-specific hydrolysis of PLA–PHB blends. This delivers simultaneous recycling and separation in a single process flow, offering a sustainable route for managing mixed bioplastic waste.
Key features:
The platform is at an early-to-mid stage of development (TRL 3–4). Prior work has demonstrated successful production and secretion of multiple enzymes (manganese peroxidase, lignin peroxidase, laccase) in P. pastoris and identified optimal strains, induction conditions, and secretion signals. The current project aims to deliver proof-of-concept validation by cloning PLA hydrolase and PHB depolymerase genes, confirming extracellular expression, and demonstrating sequential degradation of a PLA–PHB blend in a two-reactor system. Next steps toward commercialization would include scaling reactor volumes, expanding to additional PHA variants, and integrating monomer recovery and purification.
The University of Pittsburgh is a large, comprehensive public research university anchored in an urban innovation corridor with a strong translational focus. Integration with UPMC, a leading academic medical center, enables clinical studies, access to broad patient populations, and co-located clinical–engineering labs that shorten paths from discovery to deployment. A nearby research and technology district, extensive core facilities, and an engineering co-op program give companies entry points for prototyping and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DoD, and DOE. A dedicated technology transfer office provides IP strategy, licensing, startup support, and contracting for industry partners.